Antituberculosis Therapy for 2012 and Beyond

Expert Opinion on Pharmacotherapy - United Kingdom
doi 10.1517/14656566.2012.657176
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Informa Healthcare

Related search

Intravesical Therapy – BCG and Beyond

Bladder Cancer
OncologyUrology
2019English

Targeting FtsZ for Antituberculosis Drug Discovery: Noncytotoxic Taxanes as Novel Antituberculosis Agents

Journal of Medicinal Chemistry
Drug DiscoveryMolecular Medicine
2006English

From Rio 1992 to Rio 2012 and Beyond

Journal of Environment and Development
DevelopmentManagementMonitoringPlanningPolicyLawGeography
2012English

Beyond BRAF: Where Next for Melanoma Therapy?

British Journal of Cancer
Cancer ResearchOncology
2014English

Corn Production Shocks in 2012 and Beyond: Implications for Food Price Volatility

2012English

Molecularly Targeted Therapy: Imatinib and Beyond

2012English

Beyond a Moonshot: Insurance Coverage for Proton Therapy

The Lancet Oncology
Oncology
2016English

The Dark Side of Antituberculosis Therapy: Adverse Events Involving Liver Function

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
1995English

Meta-Analysis of Clinical Studies Supports the Pharmacokinetic Variability Hypothesis for Acquired Drug Resistance and Failure of Antituberculosis Therapy

Clinical Infectious Diseases
Infectious DiseasesMicrobiology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy